Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Deep Track Capital LP owned about 1.61% of Intra-Cellular Therapies worth $98,035,000 at the end of the most recent reporting period.
Finally, Royal Bank of Canada lowered their price target on Intra-Cellular Therapies from $75.00 to $71.00 and set an “outperform” rating for the company in a research report on Thursday, March 2nd.
Intra-Cellular Therapies had a negative return on equity of 35.88% and a negative net margin of 102.37%.
Intra-Cellular Therapies, Inc. has a 1-year low of $42.01 and a 1-year high of $67.05.
Intra-Cellular Therapies, Inc. ( sold 15,604 shares of the business’s stock in a transaction on Tuesday, March 28th.
Intra-Cellular Therapies () last issued its quarterly earnings data on Thursday, August 3rd.
Intra-Cellular Therapies () last posted its quarterly earnings data on Thursday, August 3rd.
Royal Bank of Canada lifted their price target on shares of Intra-Cellular Therapies from $78.00 to $79.00 and gave the company an “outperform” rating in a research report on Friday, August 4th.